CCR3 Modulation for Aging-Associated Cognitive Decline
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aging leads to structural and neurophysiological changes in the nervous system, resulting in cognitive decline and increased susceptibility to degenerative disorders, with synapse loss being a common pathological event in both normal aging and neurodegenerative diseases like Alzheimer's, posing a significant risk for cognitive impairments as the population ages.
Innovation Solution
Modulating CCR3, specifically through the eotaxin-1/CCR3 interaction, to treat aging-associated impairments, including cognitive impairments, by reducing active systemic eotaxin-1 levels or inhibiting its activity to mitigate the negative effects on neurogenesis and synaptic plasticity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If aging occurs naturally, then neuronal death is avoided, but synapse loss and neuronal function loss result in cognitive decline
Solution Approach 1:
The patent uses CCR3 as a target receptor and eotaxin-1 as a ligand to modulate neuronal function. By introducing this specific signaling pathway as an intermediary mechanism, the invention enables protection of synaptic integrity and enhancement of neurogenesis without causing neuronal death, thus resolving the contradiction between maintaining neuronal survival and preserving cognitive function.
Solution Approach 2:
The patent modulates the eotaxin-1/CCR3 interaction to change the physiological parameters of synaptic plasticity and neurogenesis. By adjusting the activation level of this signaling pathway, the invention optimizes cognitive function while maintaining neuronal survival, addressing the trade-off between neuronal preservation and cognitive performance.
2Productivity
If synapse loss is prevented, then cognitive function is maintained, but the underlying mechanism involves complex molecular pathways
Solution Approach 1:
The patent extracts and targets a specific molecular component (CCR3 receptor or eotaxin-1 ligand) from the complex network of molecular pathways involved in synaptic maintenance. By focusing on this single key element, the invention simplifies the approach to preventing synapse loss while maintaining cognitive function, avoiding the need to modulate multiple complex pathways simultaneously.
3Productivity
If eotaxin-1 levels are reduced, then synaptic plasticity is improved, but systemic eotaxin-1 modulation is required
Solution Approach 1:
The patent enables localized modulation of eotaxin-1 activity at the site of CCR3 expression in the nervous system. By targeting the receptor-ligand interaction specifically in neural tissues rather than systemically reducing eotaxin-1 throughout the body, the invention improves synaptic plasticity while minimizing the complexity and side effects associated with broad systemic treatment.
Data Source
AI summary
Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.